Late Breaking Abstract - Short 12-month regimen with intravenous linezolid for pre-XDR TB: treatment outcomes and 24 months follow-up results

N. Lytvynenko (Kyiv, Ukraine), M. Pogrebna (Kyiv, Ukraine), J. Senko (Kyiv, Ukraine), L. Protsyk (Kyiv, Ukraine), O. Chobotar (Kyiv, Ukraine), N. Grankina (Kyiv, Ukraine), M. Gumenuk (Kyiv, Ukraine)

Source: International Congress 2019 – Tuberculosis: treatment and management
Session: Tuberculosis: treatment and management
Session type: Poster Discussion
Number: 5271
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Lytvynenko (Kyiv, Ukraine), M. Pogrebna (Kyiv, Ukraine), J. Senko (Kyiv, Ukraine), L. Protsyk (Kyiv, Ukraine), O. Chobotar (Kyiv, Ukraine), N. Grankina (Kyiv, Ukraine), M. Gumenuk (Kyiv, Ukraine). Late Breaking Abstract - Short 12-month regimen with intravenous linezolid for pre-XDR TB: treatment outcomes and 24 months follow-up results. 5271

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Short 12-month regimen with intravenouse linezolid for MDR-TB:  treatment outcomes and first follow up results.
Source: International Congress 2018 – New developments in tuberculosis
Year: 2018



Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019




Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016

Outcomes of 6-9-12 months’ bedaquiline-containing regimens in MDR/XDR TB after 24 months follow up
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018




Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 314s
Year: 2001

Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015


Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study
Source: Eur Respir J 2006; 28: 980-985
Year: 2006



Systematic review of shorter 2-3 months regimens for treatment of latent tuberculosis
Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis
Year: 2013



Late Breaking Abstract - Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid - Data from 38,820 outpatients.
Source: International Congress 2019 – Comorbidities galore in respiratory patients
Year: 2019



The side effects, the outcome and the mortality of anti-tuberculosis treatment in dialyzed patients: A 10-year retrospective analysis
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015

Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis with delayed conversion over 4 months
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015

Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial
Source: International Congress 2019 – Recent developments in intensive care unit medicine
Year: 2019

Completion rates of LTBI treatment: shifting prescription from INH alone to RIF containing regimens. Observation from 1992 to 2017
Source: International Congress 2019 – Tuberculosis: a public health approach
Year: 2019


Outcomes of modified all-oral 9-month treatment regimen for rifampicin-resistant tuberculosis in Belarus
Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease
Year: 2021



Predictors of defaulting from treatment among patients with tuberculosis
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015


Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Year: 2020




First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB
Source: Eur Respir J 2016; 47:1581-1584
Year: 2016


A two-year post-treatment follow-up of multi-drug resistant tuberculosis cases who completed a programmatic MDR-TB management at the lung center of the Philippines – a preliminary report
Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis
Year: 2009



Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population
Source: Eur Respir J 2005; 26: Suppl. 49, 624s
Year: 2005

Pulmonary sequelae in patients with COVID-19: results after 3 months of follow-up
Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends
Year: 2021